Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale
01:30am, Monday, 13'th Jul 2020
(Bloomberg) -- Chinese biotech company Beigene Ltd. plans to raise $2.1 billion in a direct offering of 145.8 million shares to fund drug research and market its treatments in the U.S. and China, said
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
12:00am, Monday, 13'th Jul 2020
CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
Insider Weekends: Chairman Of Herman Miller Purchases 25,000 Shares
11:44pm, Sunday, 12'th Jul 2020
Insider buying declined significantly for a second week in a row. Notable Insider Buys: Continental Resources, Inc., W&T Offshore, Inc., Herman Miller, Inc., The Cooper Companies, Inc., Syneos Health,
Insiders Roundup: Mastercard, Eli Lilly
03:11pm, Friday, 10'th Jul 2020
Largest insider trades of the week Continue reading...
Is BeiGene, Ltd. (BGNE) A Good Stock To Buy?
08:04pm, Sunday, 05'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
iTeos Therapeutics Begins U.S. IPO Rollout
03:59pm, Thursday, 02'nd Jul 2020
iTeos Therapeutics has filed to raise $100 million in a U.S. IPO. The firm is developing drug candidates to treat solid tumors and other cancer indications. ITO
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
11:00am, Thursday, 02'nd Jul 2020
CAMBRIDGE, Mass. and BEIJING, China, July 02, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
BEIJING, China and CAMBRIDGE, Mass., July 01, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:12pm, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) * ADC Therapeutics SA (NYSE: ADCT) * Akebia Therapeu
BeiGene Announces Appointment of Angus Grant as Chief Business Executive
11:00am, Wednesday, 01'st Jul 2020
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatmen
BeiGene Begins Commercializing XGEVA® (Denosumab) in China
11:30pm, Tuesday, 30'th Jun 2020
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatmen
Preclinical data presented at the American Association for Cancer Research 2020 Virtual Annual Meeting II Ongoing Phase 1b/2 clinical trial on track to commence dose.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatmen
CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
bluebird On The Go, And Other News: The Good, Bad And Ugly Of Biopharma
09:02pm, Wednesday, 17'th Jun 2020
bluebird reports multiple positive trial data. BeiGene's blood cancer trial reports positive data. TG Therapeutics' TG-1701 reports positive interim data.
